Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
The scheme is subject to statutory and regulatory approvals as may be necessary.
The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors
Subscribe To Our Newsletter & Stay Updated